Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. provides virtual primary care through a direct-to-patient telehealth platform that combines telemedicine, laboratory access, pharmacy services, a 50-state affiliated medical group, an affiliated pharmacy and a U.S.-based patient care center. Company news commonly covers its Telehealth operating segment, recurring subscription revenue, patient sign-ups, gross margin trends and guidance.
Recurring updates also address LifeMD’s specialized care areas, including primary care, men’s and women’s health, weight management and hormone therapy. News items feature GLP-1 weight management offerings such as Wegovy and Foundayo, branded therapy access through manufacturer programs, preferred stock dividends, executive leadership changes and investor conference participation.
LifeMD has announced its acquisition of Cleared, a prominent telehealth platform specializing in allergy, asthma, and immunology treatments. The deal, valued at approximately $3.9 million, aims to enhance LifeMD's offerings and drive growth in the $13.5 billion U.S. allergy market. With more than 75 million Americans affected by allergies, this acquisition is expected to synergize with LifeMD's existing services and expand its patient base. The acquisition is anticipated to be accretive to LifeMD's Adjusted EBITDA in 2022, marking a significant step in its strategic growth.
LifeMD, Inc. (NASDAQ: LFMD) announced key executive appointments aimed at enhancing its telehealth services. Dennis Wijnker joins as CTO, bringing over 20 years in software development from Doctor Evidence, while Garett Hunter takes on the role of SVP and GM of LifeMD Primary Care, previously serving at Yumi. Their expertise in technology and marketing is expected to play a crucial role in the upcoming launch of LifeMD’s virtual primary care platform. Both received equity awards as part of their compensation packages.
LifeMD, Inc. (NASDAQ: LFMD) announced its participation in three investor conferences and one panel event in January 2022, providing opportunities for one-on-one investor meetings. Key dates include the LifeSci Partners Corporate Access Event from January 5-7, the H.C. Wainwright Bioconnect Virtual Conference on January 10 with an on-demand presentation starting at 7:00 am ET, and the Sidoti Virtual Small Cap Conference on January 19-20. LifeMD specializes in direct-to-patient telehealth services across all 50 states, offering virtual access to affordable medical care.
CEO Schreiber to discuss changes made possible via proprietary virtual care platforms
LifeMD, a leading telehealth company (NASDAQ: LFMD), announced that CEO Justin Schreiber will participate in a panel at the LifeSci Partners Corporate Access Event, happening virtually from January 5-7, 2022. Schreiber will discuss how LifeMD's virtual care technology is transforming healthcare to improve affordability and patient outcomes. The panel, titled 'Telehealth & Digital Medicine: At a Crossroads of Virtual Care,' is scheduled for January 6 at 8:30 am ET. Interested parties can register for the webcast to view the discussion.
On December 23, 2021, LifeMD announced a cash dividend of $0.622483 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP), payable on January 14, 2022. The dividend will be distributed to shareholders of record on January 4, 2022. LifeMD is a growing telehealth company providing virtual medical care across the U.S., emphasizing affordable treatment and home delivery of prescriptions.
LifeMD (NASDAQ: LFMD) will present at the Stephens Annual Investment Conference on November 29, 2021, at 9:00 AM CT / 10:00 AM ET. Management will also conduct one-on-one meetings at the event.
The conference will take place in Nashville, and details for accessing the presentation will be available via a webcast link. Interested investors can find additional information on the company's website. LifeMD is a rapidly growing telehealth company providing direct-to-patient medical care across all 50 states.
LifeMD, Inc. (NASDAQ: LFMD) reported a record revenue of $24.9 million for Q3 2021, showing a 127% increase year-over-year. The company attributes 93% of its revenue to subscriptions, up from 61% last year. Adjusted EBITDA loss improved 24% sequentially, reaching $(9.0 million), indicating ongoing enhancements in profitability. Telehealth order volume surged 153%, totaling 232,293 orders. After a recent stock offering, LifeMD is in a strong capital position to pursue further growth and aims for Adjusted EBITDA break-even by Q4 2022.
LifeMD, a telehealth company, launched its virtual care platform on November 8, 2021, aiming to provide 24/7 access to personalized healthcare across the US. The platform offers direct communication with in-house physicians, unlimited messaging, and discounted prescriptions. Initially available via invitation, public access will begin on January 1, 2022. LifeMD emphasizes addressing the shortage of primary care physicians in America, aiming to enhance healthcare accessibility and efficiency.
LifeMD, a fast-growing telehealth company, announced its participation in the Credit Suisse Virtual Annual Healthcare Conference from November 8-11, 2021. The company will present on November 11 at 10:30 am ET, providing insights into its operational strategies and growth. Investors can register for the event online. LifeMD offers cash-pay virtual medical care across all U.S. states, focusing on accessible healthcare solutions. A replay of the presentation will be available in the investor relations section of the company's website.
LifeMD, Inc. (NASDAQ: LFMD) will host a conference call on November 10, 2021, at 5:00 p.m. ET to discuss its financial results for the third quarter of fiscal 2021. The call will follow a press release with results issued beforehand. The telehealth company provides virtual medical treatments and prescription medications across the U.S. interested parties can join the call by dialing 1-877-705-6003 in the U.S. and find additional information on the company's website.